|
|
Development of a cost-effective and neurobiologically valid VR assessment tool for early detection of AD |
| 1 R21 AG073973-01 |
|
NIA |
2021 |
|
|
Feasibility and acceptability of introducing person-centered narratives in an acute care setting for people with Alzheimer's and Dementia |
| 1 R43 AG074775-01 |
|
NIA |
2021 |
|
|
Development of Nav1.1 Enhancers to Treat Alzheimer's Disease |
| 1 R44 AG071137-01A1 |
|
NIA |
2021 |
|
|
Modeling the impact of regulatory and splicing variants on cellular function in Alzheimer's disease |
| 1 RF1 AG065926-01A1 |
|
NIA |
2021 |
|
|
LRP1-tau interactions and Alzheimer Disease |
| 1 RF1 AG073236-01 |
|
NIA |
2021 |
|
|
Safety and Tolerability Studies for an Anti-Fibrin P2 Monoclonal Antibody for the Treatment of Alzheimer's Disease |
| 1 U01 AG073125-01 |
|
NIA |
2021 |
|
|
Using gamification, predictive analytics, artificial intelligence, and Alexa Voice to optimize user experience for individuals living with AD/ADRD and their caregivers |
| 2 R44 AG065081-03A1 |
|
NIA |
2021 |
|
|
Investigating spatial representation in hippocampal entorhinal circuit of knock in Alzheimers model |
| 5 F31 AG069500-02 |
|
NIA |
2021 |
|
|
The role of cell death pathways in mediating neuronal loss during the earliest stages of Alzheimer disease |
| 5 K01 AG053433-05 |
|
NIA |
2021 |
|
|
Mechanisms Linking Hearing Loss and Alzheimers Disease and Related Dementias |
| 5 K23 AG057832-04 |
|
NIA |
2021 |
